Roche reported a strong Q2 as revenue grew by 6% at CER to CHF23.6bn, while both core operating profit and core EPS (excluding a one-off divestment income in 2014) increased by 7%. Revenue growth was driven by 5% CER growth in Pharma and 7% CER growth in the Diagnostics businesses, partially offset by a 3% negative impact of unfavourable currencies. Guidance for the full year was maintained at low to mid single-digit revenue growth at CER and core EPS ahead of this.
28 Jul 2015
Resilient performance despite currency headwinds and capacity expansion investments
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Resilient performance despite currency headwinds and capacity expansion investments
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
28 Jul 2015 -
Author:
Kamla Singh -
Pages:
3
Roche reported a strong Q2 as revenue grew by 6% at CER to CHF23.6bn, while both core operating profit and core EPS (excluding a one-off divestment income in 2014) increased by 7%. Revenue growth was driven by 5% CER growth in Pharma and 7% CER growth in the Diagnostics businesses, partially offset by a 3% negative impact of unfavourable currencies. Guidance for the full year was maintained at low to mid single-digit revenue growth at CER and core EPS ahead of this.